Not_yet_recruitingNCT07584330

Chinese Overweight/Obese - Diabetes Metabolic Spectrum Cohort: An Artificial Intelligence-Driven Prospective Study

Sponsor: Zhujiang Hospital

Trial Details

ConditionOverweight and Obesity, Diabetes Mellitus, Type 2, Prediabetic State, Metabolic Syndrome
StatusNot_yet_recruiting
Participants2,800
Est. Completion1 Apr 2032
Last Updated13 May 2026

Primary Outcome

Phenotype Transition Rate; Complications in T2DM-OW/OB Group

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: 1. Able to understand and voluntarily sign the informed consent form, and willing to comply with all study requirements. 2. Age between 18 and 60 years (inclusive). 3. Meets at least one of the following overweight/obesity criteria: a) BMI ≥ 24 kg/m²; b) male waist circumference ≥ 90 cm, female waist circumference ≥ 85 cm. 4. Capable of basic smartphone operation and able to use WeChat or similar communication tools for daily communication. Exclusion Criteria: 1. Diagnosis of type 1 diabetes, latent autoimmune diabetes in adults (LADA), maturity-onset diabetes of the young (MODY), or other specific types of diabetes. 2. Endocrine or metabolic diseases that may affect body weight, including untreated thyroid disorders (hyperthyroidism: TSH \< 0.1 mIU/L with FT4 \> upper normal limit; hypothyroidism: TSH \> 10 mIU/L), Cushing syndrome, acromegaly, polycystic ovary syndrome, or hypopituitarism. 3. Severe liver disease (Child-Pugh class B or C). 4. Renal insufficiency (estimated glomerular filtration rate \< 30 mL/min/1.73 m²). 5. Severe cardiac dysfunction (New York Heart Association class III or IV). 6. Major cardiovascular or cerebrovascular event within the past 3 months (acute coronary syndrome, stroke). 7. Uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg or diastolic ≥ 110 mmHg) or uncontrolled diabetes (HbA1c ≥ 9.0%). 8. Active malignancy (diagnosed or treated within the last 3 years). 9. Inflammatory bowel disease or conditions causing malabsorption (Crohn disease, active ulcerative colitis, pancreatitis with steatorrhea). 10. Neuropsychiatric disorders (anorexia nervosa, bulimia nervosa, schizophrenia, major depression, or bipolar disorder). 11. Diseases or physical conditions that impair motor function (severe osteoarthritis, Parkinson disease, paralysis, or cardiopulmonary insufficiency). 12. Long-term use of antipsychotic drugs, systemic glucocorticoids, or other medications judged by the investigator to affect study outcomes. 13. Pregnancy or planned pregnancy during the study period. 14. History of or planned organ transplantation. 15. Inability to operate the AI-based system or comply with follow-up procedures. 16. Concurrent participation in another interventional clinical trial that may influence the results of this study. 17. Unwilling or unable to provide informed consent.

View Registry Entry

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service